{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:11:03Z","timestamp":1768439463051,"version":"3.49.0"},"reference-count":44,"publisher":"Informa UK Limited","issue":"19","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2024,6,14]]},"DOI":"10.2217\/fon-2023-1065","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T10:45:33Z","timestamp":1713782733000},"page":"1351-1366","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-8691","authenticated-orcid":false,"given":"G\u00fcnter","family":"Niegisch","sequence":"first","affiliation":[{"name":"Department of Urology, University Hospital & Medical Faculty of the Heinrich-Heine-University, D\u00fcsseldorf, 40225, Germany"},{"name":"Centre for Integrated Oncology (CIO) D\u00fcsseldorf, CIO Aachen Bonn Cologne D\u00fcsseldorf (ABCD), D\u00fcsseldorf, 40225, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3084-8654","authenticated-orcid":false,"given":"Marc-Oliver","family":"Grimm","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Jena, Jena, 07747, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4698-1628","authenticated-orcid":false,"given":"Fraence","family":"Hardtstock","sequence":"additional","affiliation":[{"name":"Cytel, Berlin, 10785, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5816-0611","authenticated-orcid":false,"given":"Julia","family":"Krieger","sequence":"additional","affiliation":[{"name":"Cytel, Berlin, 10785, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-511X","authenticated-orcid":false,"given":"Alexandra","family":"Starry","sequence":"additional","affiliation":[{"name":"Cytel, Berlin, 10785, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Osowski","sequence":"additional","affiliation":[{"name":"Merck Healthcare Germany GmbH, Weiterstadt, 64331, Germany, an affiliate of Merck KGaA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Guenther","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA, Darmstadt, 64293, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1630-8080","authenticated-orcid":false,"given":"Barthold","family":"Deiters","sequence":"additional","affiliation":[{"name":"GWQ ServicePlus AG, D\u00fcsseldorf, 40549, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Maywald","sequence":"additional","affiliation":[{"name":"Drug department, AOK PLUS, Dresden, 01058, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8932-6426","authenticated-orcid":false,"given":"Thomas","family":"Wilke","sequence":"additional","affiliation":[{"name":"IPAM e.V., Wismar, 23966, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mairead","family":"Kearney","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA, Darmstadt, 64293, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"e_1_3_7_3_1","unstructured":"Witjes JA Bruins HM Carri\u00f3n A et al. EAU guidelines on muscle-invasive and metastatic bladder cancer. 2022. Available from: https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer"},{"key":"e_1_3_7_4_1","volume-title":"World Cancer Report: Cancer Research for Cancer Prevention.","author":"Wild CP","year":"2020","unstructured":"Wild CP, Weiderpass E, Stewart BW et al. World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer; 2020. Available from: www.iarc.who.int\/cards_page\/world-cancer-report\/"},{"key":"e_1_3_7_5_1","unstructured":"World Health Organization. Bladder fact sheet. 2020. Available from: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/30-Bladder-fact-sheet.pdf"},{"key":"e_1_3_7_6_1","volume-title":"Cancer in Germany 2019\/2020.","author":"Robert Koch-Institut","year":"2021","unstructured":"Robert Koch-Institut. Cancer in Germany 2019\/2020. Berlin, Germany; 2021. Available from: www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/krebs_in_deutschland_inhalt.html"},{"key":"e_1_3_7_7_1","unstructured":"National Cancer Institute. Cancer Stat Facts: Bladder Cancer. Bethesda MD; 2022. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html"},{"key":"e_1_3_7_8_1","volume-title":"Leitlinie Blasenkarzinom (Urothelkarzinom).","author":"de Wit M","year":"2017","unstructured":"de Wit M, Bauernhofer T, Bokemeyer C et al. Leitlinie Blasenkarzinom (Urothelkarzinom). Berlin: DGHO Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie e.V.; 2017. Available from: https:\/\/repository.publisso.de\/resource\/frl:6419224\/data"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.07.025"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1591424"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00167"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.23162"},{"key":"e_1_3_7_13_1","unstructured":"ClinicalTrials.gov. Study of pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy alone in urothelial carcinoma (MK-3475-361\/KEYNOTE-361). Bethesda MD: National Library of Medicine US; 2021 [updated 2022 Oct 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02853305"},{"key":"e_1_3_7_14_1","unstructured":"ClinicalTrials.gov. Study of atezolizumab as monotherapy and in combination with platinum-based chemotherapy in participants with untreated locally advanced or metastatic urothelial carcinoma (IMvigor130). Bethesda MD: National Library of Medicine US; 2016 [updated 2022 Oct 14]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02807636"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"e_1_3_7_16_1","volume-title":"Atezolizumab (Urothelkarzinom nach Chemotherapie) - Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V.","author":"Institute for Quality and Efficiency in Health Care (IQWiG)","year":"2017","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Atezolizumab (Urothelkarzinom nach Chemotherapie) - Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V. Cologne, Germany; 2017. Available from: www.iqwig.de\/download\/a17-52_atezolizumab_nutzenbewertung-35a-sgb-v_v1-0.pdf"},{"key":"e_1_3_7_17_1","volume-title":"Pembrolizumab (Urothelkarzinom Erstlinientherapie) - Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V.","author":"Institute for Quality and Efficiency in Health Care (IQWiG)","year":"2017","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Pembrolizumab (Urothelkarzinom Erstlinientherapie) - Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V. Cologne, Germany; 2017. Available from: www.iqwig.de\/download\/a21-34_pembrolizumab_nutzenbewertung-35a-sgb-v_v1-0.pdf"},{"key":"e_1_3_7_18_1","volume-title":"Atezolizumab (Urothelkarzinom Erstlinientherapie) \u2013 Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V.","author":"Institute for Quality and Efficiency in Health Care (IQWiG)","year":"2017","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Atezolizumab (Urothelkarzinom Erstlinientherapie) \u2013 Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V. Cologne, Germany; 2017. Available from: www.iqwig.de\/download\/a17-51_atezolizumab_nutzenbewertung-35a-sgb-v_v1-0.pdf"},{"key":"e_1_3_7_19_1","volume-title":"Nivolumab (Urothelkarzinom) \u2013 Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V.","author":"Institute for Quality and Efficiency in Health Care (IQWiG)","year":"2017","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Nivolumab (Urothelkarzinom) \u2013 Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V. Cologne, Germany; 2017. Available from: www.iqwig.de\/download\/a17-29_nivolumab_nutzenbewertung-35a-sgb-v_v1-0.pdf?rev=117386"},{"key":"e_1_3_7_20_1","volume-title":"Nivolumab (Urothelkarzinom, adjuvant) \u2013 Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V.","author":"Institute for Quality and Efficiency in Health Care (IQWiG)","year":"2022","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Nivolumab (Urothelkarzinom, adjuvant) \u2013 Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V. Cologne, Germany; 2022. Available from: www.iqwig.de\/download\/a22-53_nivolumab_nutzenbewertung-35a-sgb-v_v1-0.pdf"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.09.026"},{"key":"e_1_3_7_22_1","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK AWMF). S3-Leitlinie Fr\u00fcherkennung Diagnose Therapie und Nachsorge des Harnblasenkarzinoms Langversion 2.0. 2020. Available from: www.leitlinienprogramm-onkologie.de\/leitlinien\/harnblasenkarzinom\/"},{"key":"e_1_3_7_23_1","volume-title":"Avelumab (Urothelkarzinom) \u2013 Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V.","author":"Institute for Quality and Efficiency in Health Care (IQWiG)","year":"2021","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Avelumab (Urothelkarzinom) \u2013 Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V. Cologne, Germany; 2021. Available from: www.iqwig.de\/download\/a21-23_avelumab_nutzenbewertung-35a-sgb-v_v1-0.pdf"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"e_1_3_7_25_1","volume-title":"Summary of product characteristics.","author":"Bavencio (avelumab)","year":"2023","unstructured":"Bavencio (avelumab). Summary of product characteristics. Merck Europe B.V., Amsterdam, Netherlands, an affiliate of Merck KGaA; 2023."},{"key":"e_1_3_7_26_1","volume-title":"Enfortumab Vedotin (Urothelkarzinom) \u2013 Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V.","author":"Institute for Quality and Efficiency in Health Care (IQWiG)","year":"2022","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Enfortumab Vedotin (Urothelkarzinom) \u2013 Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V. Cologne, Germany; 2022. Available from: www.iqwig.de\/download\/a22-61_enfortumab-vedotin_nutzenbewertung-35a-sgb-v_v1-0.pdf"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0298"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2020.08.005"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2012.000829"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.3758\/s13428-018-1123-7"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X0800800403"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.466"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1828"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrc.2014.08.003"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2020.04.03"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.11.014"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02694-9"},{"key":"e_1_3_7_38_1","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK AWMF). S3-Leitlinie Fr\u00fcherkennung Diagnose Therapie und Nachsorge des Harnblasenkarzinoms Langversion 1.1. Deutsche Krebsgesellschaft Deutsche Krebshilfe AWMF; 2016. Available from: http:\/\/leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Blasenkarzinom\/LL_Harnblasenkarzinom_Langversion_1.1.pdf"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9797"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.103"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-018-0540-8"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2021.07.002"},{"issue":"10","key":"e_1_3_7_43_1","first-page":"e53","article-title":"[Validation of SHI claims data exemplified by gender-specific diagnoses]","volume":"78","author":"Hartmann J","year":"2016","unstructured":"Hartmann J, Weidmann C, Biehle R. [Validation of SHI claims data exemplified by gender-specific diagnoses]. Gesundheitswesen. 2016;78(10):e53\u2013e58.","journal-title":"Gesundheitswesen."},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028223"},{"issue":"6","key":"e_1_3_7_45_1","article-title":"Treatment patterns, indicators of receiving systemic treatment, and clinical outcomes in metastatic urothelial carcinoma: a retrospective analysis of real-world data in Germany","volume":"41","author":"Niegisch G","year":"2023","unstructured":"Niegisch G, Grimm M-O, Hardtstock F et al. Treatment patterns, indicators of receiving systemic treatment, and clinical outcomes in metastatic urothelial carcinoma: a retrospective analysis of real-world data in Germany. J. Clin. Oncol. 2023;41(Suppl. 6):Abstract 464.","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1035"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-1065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T22:26:22Z","timestamp":1744064782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-1065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":44,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,6,14]]}},"alternative-id":["10.2217\/fon-2023-1065"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-1065","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}